Ep. 362 - AACR: Data and de-risking

Bispecific antibodies and dual-payload antibody-drug conjugates were in the spotlight at this year’s American Association for Cancer Research meeting in San Diego as biotechs unveiled their latest preclinical and first-in-human oncology data. On a special edition of the BioCentury This Week podcast, IQVIA Biotech CMO James Kyle Bryan joins BioCentury’s analysts to discuss what AACR revealed about modalities gaining traction, plus shares his perspective on de-risking clinical development and eliminating the “white space” that delays biotechs’ timelines in the clinic. This episode of the BioCentury This Week podcast was brought to you by IQVIA Biotech . View full story: 00:01 - Sponsor Message: IQVIA Biotech 01:43 – AACR Early Signals 05:17 – Antibody Innovation 09:22 – Dual Payload ADCs 13:48 – De-Risking Drug Development 19:16 – Looking Ahead to ASCO To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

You can listen to Ep. 362 - AACR: Data and de-risking online on Radio and Podcast. Open the player on this page to stream the available audio.

Ep. 362 - AACR: Data and de-risking is an episode from BioCentury This Week by BioCentury.

This episode is 25:06 long.

This episode was published on Apr 23, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from BioCentury This Week when more episodes are available from the podcast feed.